VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

TAS-102 in Metastatic Colorectal Cancer

Panelists:Fadi Braiteh, MD, Comprehensive Cancer Centers of Nevada; Richard M. Goldberg, MD, Ohio State University Comprehensive Cancer Center; Howard S. Hochster, MD, Yale Cancer Center; John L. Marshall, MD, Georgetown University Hospital
Published: Thursday, Aug 20, 2015

 
TAS-102 is an oral investigational compound being evaluated as a treatment for patients with refractory metastatic colorectal cancer (CRC). It is an antimetabolite that is similar to 5-fluorouracil (5-FU), states Howard S. Hochster, MD. In the phase III RECOURSE trial, TAS-102 demonstrated an improvement in survival in heavily pre-treated patients with metastatic colorectal cancer compared with placebo. The drug by itself has a 12-minute half-life and is administered twice daily, 10 days a month.

In February 2015, the FDA accepted a new drug application for TAS-102, based on the RECOURSE trial. For patients treated with TAS-102, the median OS was 7.1 months compared with 5.3 months with placebo (HR = 0.68; P <.0001). The median PFS in the TAS-102 arm was 2 months versus 1.7 months with placebo (HR = 0.48; P <.0001). 

The agent is effective in cell lines that are refractory to 5-FU, notes Richard L. Goldberg, MD. Its toxicity profile appears to be more predictable over its main competitor, capecitabine. Toxicities of TAS-102 mainly include mild hematologic toxicity, such as delayed bone marrow recovery.

The drug is likely to move into earlier settings in combination with other agents, predicts Fadi Braiteh, MD. There will be a learning curve in clinical practice, Braiteh adds, but clinical trials will help answer questions as to the drug’s efficacy earlier in the disease course.
Slider Left
Slider Right

 
TAS-102 is an oral investigational compound being evaluated as a treatment for patients with refractory metastatic colorectal cancer (CRC). It is an antimetabolite that is similar to 5-fluorouracil (5-FU), states Howard S. Hochster, MD. In the phase III RECOURSE trial, TAS-102 demonstrated an improvement in survival in heavily pre-treated patients with metastatic colorectal cancer compared with placebo. The drug by itself has a 12-minute half-life and is administered twice daily, 10 days a month.

In February 2015, the FDA accepted a new drug application for TAS-102, based on the RECOURSE trial. For patients treated with TAS-102, the median OS was 7.1 months compared with 5.3 months with placebo (HR = 0.68; P <.0001). The median PFS in the TAS-102 arm was 2 months versus 1.7 months with placebo (HR = 0.48; P <.0001). 

The agent is effective in cell lines that are refractory to 5-FU, notes Richard L. Goldberg, MD. Its toxicity profile appears to be more predictable over its main competitor, capecitabine. Toxicities of TAS-102 mainly include mild hematologic toxicity, such as delayed bone marrow recovery.

The drug is likely to move into earlier settings in combination with other agents, predicts Fadi Braiteh, MD. There will be a learning curve in clinical practice, Braiteh adds, but clinical trials will help answer questions as to the drug’s efficacy earlier in the disease course.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x